| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | Director | Common Stock | 25,075 | $1.13 M | $45.00 | Jun 18, 2024 | Direct |
| Syros Pharmaceuticals, Inc. | Director | Common Stock | 12,000 | $59.4 K | $4.95 | Jun 1, 2024 | Direct |
| MCKESSON CORP | Director | Restricted Stock Units (RSUs) | 56 | $31.4 K | $560.99 | Jun 3, 2024 | Direct |
| Syros Pharmaceuticals, Inc. | Director | Restricted Stock Units | 4,000 | $19.8 K | $4.95 | Jun 5, 2024 | Direct |
| Ultragenyx Pharmaceutical Inc. | Director | Stock Option (Right to Buy) | 9,900 | Jun 18, 2024 | Direct | ||
| Syros Pharmaceuticals, Inc. | Director | Stock Option (right to buy) | 6,000 | Jun 5, 2024 | Direct | ||
| ALEXION PHARMACEUTICALS, INC. | Director | Common Stock, par value $.0001 per share | 0 | $177.00 | Jul 21, 2021 | Direct |